The Australian Technical Advisory Group on Immunisation (ATAGI) has released a statement to address the current risk of COVID-19 in NSW and the ongoing constraints on Comirnaty (Pfizer) vaccine supplies.
Due to increasing risk of COVID-19 and ongoing constraints of Comirnaty (Pfizer) supplies, ATAGI recommends all individuals aged 18 years and above in greater Sydney, including adults under 60 years of age, should strongly consider getting vaccinated with any available vaccine including COVID-19 Vaccine AstraZeneca.
ATAGI also advises that people in areas where outbreaks are occurring can receive the second dose of the AstraZeneca vaccine 4 to 8 weeks after the first dose, rather than the usual 12 weeks, to bring forward optimal protection. ATAGI also reinforces that the interval between the first and second doses of Comirnaty (Pfizer) is 3-6 weeks, providing flexibility in managing available supplies of vaccines, whilst also noting two doses are required for optimal protection.
In addition to being informed of the benefits and risks and give informed consent, it is advised that people who receive COVID-19 Vaccine AstraZeneca should be aware of the symptoms of thrombosis with thrombocytopenia syndrome (TTS), and when to seek prompt medical attention.
To read the statement in full, please click the link below:
ATAGI Statement: Response to NSW COVID-19 outbreak 24th July 2021